A DNA nanodevice-based vaccine for cancer immunotherapy

Shaoli Liu, Qiao Jiang, Xiao Zhao, Ruifang Zhao, Yuanning Wang, Yiming Wang, Jianbing Liu, Yingxu Shang, Shuai Zhao, Tiantian Wu, Yinlong Zhang, Guangjun Nie, Baoquan Ding

Research output: Contribution to journalArticle

Abstract

A major challenge in cancer vaccine therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA ‘locking strands’ outside the nanostructures enables the opening of the vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge.

Original languageEnglish (US)
JournalNature materials
DOIs
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Chemistry(all)
  • Materials Science(all)
  • Condensed Matter Physics
  • Mechanics of Materials
  • Mechanical Engineering

Fingerprint Dive into the research topics of 'A DNA nanodevice-based vaccine for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this